INTRODUCTION
Trigeminal neuralgia (TN) is a disease characterized by paroxysmal and refractory severe pain occurring along the trigeminal nerve. The pain is strictly limited to the distribution of the fifth cranial nerve and can involve one, two or even three branches. Bilateral cases are very rare. The management of trigeminal neuralgia continues to be a major therapeutic challenge. Current treatments are mainly divided into medical treatments and surgery and medication is often the first-line treatment. For this study, the affected nerve was blocked with 1.5 ml of 0.5% bupivacaine HCl. Patient’s visual analogue scores (VAS) were recorded on preoperative day and on post operative at day 3, 7 days, 15 days. There was a significant difference between mean preoperative and postoperative VAS value. Preoperative value was 83.10 ± 6.06, at postoperative 3 days was 39.60 ± 7.86, at postoperative 7 days was 16.25 ± 6.46 and at postoperative 15 days was 3.30 ± 3.19. So it can be concluded that administration of 1.5 ml of 0.5% bupivacaine HCl nerve block at regular interval can be used as treatment for patients who are affected by the side effects from high-dose antiepileptic drugs.

STUDY TO ASSESS THE STATUS OF BUPIVACAINE HYDROCHLORIDE IN THE MANAGEMENT OF ESSENTIAL TRIGEMINAL NEURALGIA

SHOHDA KHATUN1, ASHIS KUMAR BISWAS2, RAJAN KARMAKAR2, SOJEEB DHAR2, MST. MAHBUBA KAFIA PARVIN2
1Senior Consultant, Department of Oral & Maxillofacial Surgery, BSMMU, 2Department of Oral & Maxillofacial Surgery, BSMMU

ABSTRACT
Trigeminal neuralgia (TN) is a rare form of neuropathic facial pain characterized by severe paroxysmal pain in the face. The treatment of trigeminal neuropathic pain disorder is a major therapeutic challenge. Medical therapy often fails either due to poor responses to drugs or to unacceptable side effects and for those cases local anesthesia should be considered. Twenty patients (nine men and eleven women) who were diagnosed with TN previously and were not responsive to further medical treatment were selected for treatment. For this study, the affected nerve was blocked with 1.5 ml of 0.5% bupivacaine HCl. Patient’s visual analogue scores (VAS) were recorded on preoperative day and on post operative at day 3, 7 days, 15 days. There was a significant difference between mean preoperative and postoperative VAS value. Preoperative value was 83.10 ± 6.06, at postoperative 3 days was 39.60 ± 7.86, at postoperative 7 days was 16.25 ± 6.46 and at postoperative 15 days was 3.30 ± 3.19. So it can be concluded that administration of 1.5 ml of 0.5% bupivacaine HCl nerve block at regular interval can be used as treatment for patients who are affected by the side effects from high-dose antiepileptic drugs.

Key words: Trigeminal neuralgia, Bupivacaine, Visual Analogue Score.

(International Journal of Physiol Pharmacoal 2010; 26(1&2) : 30-33)

INTRODUCTION
Trigeminal neuralgia (TN) is a disease characterized by paroxysmal and refractory severe pain occurring along the trigeminal nerve. The pain is strictly limited to the distribution of the fifth cranial nerve and can involve one, two or even three branches. Bilateral cases are very rare. The management of trigeminal neuralgia continues to be a major therapeutic challenge. Current treatments are mainly divided into medical treatments and surgery and medication is often the first-line treatment. Traditionally, patients are offered surgical options only when medications fail or severe side effects develop. Although current treatment is initially medical, medical treatment fails in 30% of cases because of inadequate pain control or side effects of the drugs used. Surgery can alleviate the pain, but is associated with morbidity and mortality and is not always effective. Phenytoin, carbamazepine, clonazepam, gabapentin, and baclofen have also been used as anti neuralgic drugs. Medical management with anticonvulsant (antiepileptic) drugs has debilitating side effects and the drugs eventually lose effectiveness. The medical treatments (anticonvulsant medications) eliminate or significantly reduce the pain in approximately 75% of patients and are considered the treatment of choice for incident cases of TN. Unfortunately, the relief provided by medical therapy generally decreases over time. When medications fail to relieve TN pain attacks, it is important to reduce the risk of severe side effects of surgery and surgical sequelae seen in cranial surgery considering the mean age of TN patients. Nerve block with local anesthetics is appropriate in such cases because this treatment is reversible and non traumatic so it can be effectively used. In this study we used nerve block with a long-lasting local anesthetic for treating TN as a minor intervention to decrease the risk of intracranial neurosurgery complications, eliminate the disadvantages of other peripheral interventions and patient suffering from side effects of carbamazipine or on whom carbamazipine is no longer effective as a treatment of trigeminal neuralgia and presenting a solution for patients in such difficult situation.

MATERIALS AND METHODS
The study involved 20 patients (nine men and eleven women) with essential trigeminal neuralgia. The study protocol was explained to the patients in detail before obtaining the informed consent from the patients. Only patients suffering from paroxysmal pain were included in order to standardize and focus the study. The diagnosis
of idiopathic TN was based on paroxysmal attacks of pain in one or several branches of the trigeminal nerve with pain-free intervals trigger areas, pain-triggering stimuli and absence of signs of a trigeminal nerve organic lesion. All the patients were suffering from various side effect of carbamazepine as altered liver function and some of the patients had attack of Steven Jonson syndrome were included for study. The patient who had history of any previous surgical treatment by cryo-surgery or microvascular decompression and alcohol block were excluded.

Evaluation

Visual an alogue scale (VAS; 100- mm line with 0 signifying no pain and 100 mm signifying worst pain imaginable) was used to measure pain. Torough discussion was done with the patient before procedure about the visual analogue scale⁶. Patient were instructed to score pain pre-operatively. Then 1.5 ml of 0.5% bupivacaine injection is given at each branch of affected nerve. Then carefully scored the pain by patient at 3 days. If patient complains of moderate pain then another increased dose of bupivacaine (3 ml) was given and scored after 7 days. If further patient complained of pain then another increased dose of (maximum 10 ml) bupivacaine is given at specific branch and observed for 15 days. Then patient was again instructed to score the pain.

Data collection technique and data analysis

After the completion of the procedure, a standardized structured data collection sheet was used to collect necessary information of the study subject. Patients were stratified by gender and affected branch. Clinical characteristics of the samples, and pre nerve block and post nerve block VAS scores were evaluated by the two-sample paired t test. The data were analyzed using SPSS 10.0.

RESULT

The mean age of the patients was 50.55±8.13 years (Table 1). In our study group, 8 patients had been suffered from maxillary and 12 from mandibular trigeminal neuralgia (Table 1). They were taking carbamazepine for 5.35±1.26 years. There was a significant difference between mean preoperative and postoperative VAS value at day 3, 7days, and 15 days. Preoperative score was 83.10±6.06, at postoperative 3 days score was 39.60±7.86, at postoperative 7 days was 16.25±6.46 and at postoperative 15 days was 3.30±3.19. From paired sample test (T test) it was found that the VAS score was highly significant when comparison was done between preoperative scores with postoperative 3 days, 7days, 15 days individually.

<table>
<thead>
<tr>
<th>Table-I</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographic profile of the patients at the beginning of the study</td>
</tr>
<tr>
<td>Mean ±SD</td>
</tr>
<tr>
<td>Age</td>
</tr>
<tr>
<td>Time of disease treated with carbamazepine</td>
</tr>
<tr>
<td>Male:Female ratio</td>
</tr>
<tr>
<td>Maxillary nerve involvement</td>
</tr>
<tr>
<td>Mandibular nerve involvement</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table-II</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean VAS with Std at preoperative, postoperative 3 days, 7days, 15 days and comparison of preoperative mean VAS with postoperative 3 days, 7days, 15 days mean VAS</td>
</tr>
<tr>
<td>VAS Score</td>
</tr>
<tr>
<td>Mean ±SD value</td>
</tr>
<tr>
<td>pre-operative</td>
</tr>
<tr>
<td>Response of 1st dose at 3 days</td>
</tr>
<tr>
<td>Response of 2nd dose at 7 days</td>
</tr>
<tr>
<td>Response of 3rd dose at 15 days</td>
</tr>
</tbody>
</table>

P value <0.05 is significant. * means highly significant.

Fig.-1: Change of patient VSA means after bupivacaine HCL administration at affected nerve branch

DISCUSSION

The ideal goal of the management of trigeminal neuralgia is to achieve long-term total analgesia. Goto et al¹⁰ and Radwan et al¹¹ found peripheral nerve block
using high concentrations of local anesthetics prolongs the analgesic effect in patients with TN, without adverse effects. Umino et al. reported that TN block with local anesthetics is reversible and non-traumatic and is appropriate for further surgical interventions such as microvascular decompression. Amir et al. Clinical and experimental data indicate that changes in the expression of voltage-gated sodium channels play a key role in the pathogenesis of neuropathic pain and that drugs that block these channels are potentially therapeutic in TN. In addition, recent data show that local anesthetics may have pain-relieving actions at targets other than sodium channels; these targets include neuronal G protein-coupled receptors and binding sites on immune cells. One postulated mechanism for the long-term effect of local anesthetics on the trigeminal nerve is Wallerian degeneration. Histologically, the extrafascicular administration of local anesthetics at clinical concentrations can alter perineural permeability, causing endoneurial oedema, increased endoneurial fluid pressure, and Wallerian degeneration with Schwann cell injury and axonal dystrophy which may reduce allodynia, hyperalgesia, and trigger point hypersensitivity. Seventeen patients with long-lasting idiopathic trigeminal neuralgia were treated by Stajcic et al. with weekly peripheral streptomycin/lidocaine (S/L) or lidocaine alone injections, in a double blind controlled study. Eight patients responded initially to the treatment in the S/L group and three patients in the lidocaine group. Pain recurred in four patients from the S/L group within two weeks and six months following the last injection. One patient from the lidocaine group remained pain-free for eight months. At the final assessment, three patients from the S/L group and two patients from the lidocaine group remained pain-free up to 30 months. They also reported that sensory functions of the injected nerves were not affected after repeated injections as in our study. Continuous nerve block with bupivacaine HCl using an indwelling catheter has not been studied for oro-facial injury and axonal dystrophy which may reduce allodynia, hyperalgesia, and trigger point hypersensitivity. Seventeen patients with long-lasting idiopathic trigeminal neuralgia were treated by Stajcic et al. with weekly peripheral streptomycin/lidocaine (S/L) or lidocaine alone injections, in a double blind controlled study. Eight patients responded initially to the treatment in the S/L group and three patients in the lidocaine group. Pain recurred in four patients from the S/L group within two weeks and six months following the last injection. One patient from the lidocaine group remained pain-free for eight months. At the final assessment, three patients from the S/L group and two patients from the lidocaine group remained pain-free up to 30 months. They also reported that sensory functions of the injected nerves were not affected after repeated injections as in our study.

**CONCLUSION**

The nerve block with 1.5ml of 0.5% bupivacaine injection for those patients who are unable to tolerate high doses of antiepileptic drugs, we observed a significant improvement in pain relief with this method without surgery.

**REFERENCES**


